Document is current
Any future updates will be listed below
-
Authors
Bishara, Isaac
Cosgrove, Patrick A.
Majumdar, Sumana
Egelston, Colt A.
Flores, Oscar Colunga
Nakamura, Brad
Ruel, Nora
Frankel, Paul H.
Yost, Susan E.
Chang, Sue
Jung, Alexander
Cristea, Mihaela
Raoof, Mustafa
Bild, Andrea H.
Nath, Aritro
Dellinger, Thanh H.
-
Funding
Funding for this research was provided by:
National Cancer Institute (P30CA033572)
National Cancer Institute (P30CA033572)
National Cancer Institute (P30CA033572)
National Cancer Institute (P30CA033572)
National Cancer Institute (P30CA033572)
National Cancer Institute (P30CA033572)
National Cancer Institute (P30CA033572)
National Cancer Institute (P30CA033572)
National Cancer Institute (P30CA033572)
National Cancer Institute (P30CA033572)
National Cancer Institute (P30CA033572)
National Cancer Institute (P30CA033572)
National Cancer Institute (P30CA033572)
National Cancer Institute (P30CA033572)
National Cancer Institute (P30CA033572)
National Cancer Institute (P30CA033572)
- License Information
-
More Information
Article History
Received: 20 May 2025
Accepted: 5 November 2025
First Online: 14 December 2025
Competing interests
: T.H.D. and M.R. received nebulizer devices from Reger free of cost for this PIPAC clinical trial. M.C. is an employee of Regeneron Pharmaceuticals Inc. and holds stock and/or stock options in the company as part of their employment compensation. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
